No annual revenue total was found in Lakewood-Amedex Biotherapeutics Inc.'s SEC filings.
Lakewood-Amedex Biotherapeutics Inc. (LABT) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $4.6 million in cash and investments and $101,619 in total debt.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$4.48M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LABT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- University Park, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2079272
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 29, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 15, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jun 17, 2026 | Jun 15, 2026 |
| 10-Q | Quarterly report | May 22, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 28, 2026 | Apr 24, 2026 |
All 44 Lakewood-Amedex Biotherapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.